These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30398345)

  • 1. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
    Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
    J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.
    Wu X; McKay C; Pett C; Yu J; Schorlemer M; Ramadan S; Lang S; Behren S; Westerlind U; Finn MG; Huang X
    ACS Chem Biol; 2019 Oct; 14(10):2176-2184. PubMed ID: 31498587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
    Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
    Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1.
    Musselli C; Ragupathi G; Gilewski T; Panageas KS; Spinat Y; Livingston PO
    Int J Cancer; 2002 Feb; 97(5):660-7. PubMed ID: 11807794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
    Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
    Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
    Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
    Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines.
    Xiao A; Zheng XJ; Song C; Gui Y; Huo CX; Ye XS
    Org Biomol Chem; 2016 Jul; 14(30):7226-37. PubMed ID: 27380866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
    Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
    ChemMedChem; 2017 Sep; 12(17):1424-1428. PubMed ID: 28675699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and immunological evaluation of the unnatural β-linked mucin-1 Thomsen-Friedenreich conjugate.
    Wu X; McFall-Boegeman H; Rashidijahanabad Z; Liu K; Pett C; Yu J; Schorlemer M; Ramadan S; Behren S; Westerlind U; Huang X
    Org Biomol Chem; 2021 Mar; 19(11):2448-2455. PubMed ID: 33645601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).
    Kohlgraf KG; Gawron AJ; Higashi M; VanLith ML; Shen X; Caffrey TC; Anderson JM; Hollingsworth MA
    Cancer Immunol Immunother; 2004 Dec; 53(12):1068-84. PubMed ID: 15696607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
    Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
    Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
    Ryan SO; Turner MS; Gariépy J; Finn OJ
    Cancer Res; 2010 Jul; 70(14):5788-96. PubMed ID: 20587526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.
    Yin Z; Wu X; Kaczanowska K; Sungsuwan S; Comellas Aragones M; Pett C; Yu J; Baniel C; Westerlind U; Finn MG; Huang X
    ACS Chem Biol; 2018 Jun; 13(6):1668-1676. PubMed ID: 29782143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
    Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine.
    Qi W; Schultes BC; Liu D; Kuzma M; Decker W; Madiyalakan R
    Hybrid Hybridomics; 2001; 20(5-6):313-24. PubMed ID: 11839249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
    Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
    Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
    Sarkar S; Salyer AC; Wall KA; Sucheck SJ
    Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.